Convenor: Professor Carmel Hawley
Carmel Hawley will present an update on data and safety monitoring boards for clinical trials. She will discuss: documents providing guidance around these boards and how they are approaching new challenges; recommendations for the organisational structure; membership of DSMB, role of the chair, and conduct of meetings; responsibilities of the DSMB; conflicts of interest; sponsor responsibilities; finances for DSMB activities; handling liability; logistics of preparing for and conducting the meeting; principles of open and closed sessions; reaching a consensus and making recommendations; preparing the outline of a charter and dummy report; timetable for data cut, snapshot and distribution of data to DSMB members; presenting the data – format; role of unblinded statistician and interaction and responsiveness to DSMB members, particularly DSMB statistician; data presentation unmasked by treatment group? ; approaches to stopping rules for safety, efficacy or futility or logistics; what happens at the end of the study; dealing with tricky situations; modifying monitoring boards to make them fit for purpose.
Carmel Hawley MB BS (Hons) M.Med Sci (Medical Statistics) FRACP, is a physician researcher and Clinical Trialist. Her clinical expertise is in Nephrology and is currently Assistant Director for the Haemodialysis program at the Princess Alexandra Hospital, Brisbane, Queensland, Australia, Professor of Medicine UQ and the Inaugural Chair of the Executive Operations Secretariat for the Australasian Kidney Trials Network (AKTN), a collaborative research network that has to date enabled over 18 multi-centre investigator-initiated clinical trials, many in collaboration with international research partners. She has been involved in DSMB activities for 15 years for activities related to investigator-initiated trials. Professor Hawley is a Fellow of the Academy of Health and Medical Sciences, and a key member of several national and international collaborations. She has published over 400 peer-reviewed articles and has been the recipient of upwards of $47,800,000 in research grant funding, primarily from the National Health and Medical Research Council’s federal grant program. In recognition of her significant contribution to the field of nephrology research, in 2018 Professor Hawley was awarded Kidney Health Australia’s highest accolade, the Kincaid-Smith medal.
How do adaptive trial sizes work?
What is an adaptive clinical trial?
What is response adaptive randomisation?
Data Safety and Monitoring Boards (DSMB) for Adaptive Trials Webinar video
Data Safety and Monitoring Boards (DSMB) for Adaptive Trials Webinar slides
ACTA Trial of the Year Award 2020 guidelines and nomination forms
Bayesian adaptive randomised clinical trials flyer
ACTA STInG grant advice for trial statisticians
ACTA STInG Notes from Members’ meeting, October 2019
Adaptive Design Clinical Trials
Hackathon of Novel Trial Designs part two
Hackathon of Novel Trial Designs part one
Studies Within A Trial SWATs webinar
Innovative Trial Design and Conduct Reference Group Objectives and Directions
ACTA STInG 2017 Member Survey Results
Novel approaches to healthcare effectiveness research outside Australia
ACTA STInG Submission to the NHMRC Structural Review
Webinar: Data Safety and Monitoring Boards for Adaptive Trials
Bayesian Adaptive Randomised Clinical Trials Workshop, Sydney
Bayesian Adaptive Randomised Clinical Trials Workshop, Melbourne
Bayesian Adaptive Trials Workshops: Perth
Workshop: Pragmatic randomised trial designs for evaluating health policy and practice change interventions